Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Professor Rikard Holmdahl
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
The agreement will support Cyxone to develop their drug candidates T20K and Rabeximod and bring them closer to the market.